Senzime develops patient-oriented systems enabling automated and continuous monitoring of vital substances such as glucose and lactate in blood and tissue. Based on Senzime's patented biosensor technology, the company offers complete patient monitoring... Log in to view full profile systems for the health care market. Senzime's products consist of the CliniSenz Analyzer and OnZurf Probe that make it possible, among other things, to detect post-operative complications significantly earlier than by conventional methods, thus contributing to improved patient care and lower health care costs. The company's share is listed on Aktietorget, Stockholm.
In May 2016 Senzime acquired Acacia Designs. Acacia is a clinical innovation company developing solutions to enable safer surgery. Acacia originates from research at Mayo Clinic, USA, and has developed novel, patent pending solutions for monitoring patients undergoing anesthesia to determine when it is safe to wake up the patient and allow spontaneous breathing following surgery. The merger of Senzime’s and Acacia’s businesses creates a company with a broader offering of systems and product that continuously monitor biological and physiological processes in patients during and after surgery. Through this acquisition, Senzime obtains a significantly increased market potential.